On February 11, 2016, Dr. Larry Altstiel resigned from his position as a member of the board of directors of Neurotrope, Inc. and its subsidiaries and as a member of all committees of the Board on which he serves. Dr. Altstiel's resignation was not related to any disagreement with the Board on any matter relating to the operations, policies or practices of the Company. On February 15, 2016, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Dr. Susanne Wilke, Ph.D., M.B.A., as a member of the Company's Board effective immediately, to fill the vacancy created by the resignation of Dr. Altstiel from the Board and to hold office until her successor is duly elected and qualified.

Dr. Wilke will serve on the Audit Committee, the Nominating and Corporate Governance Committee and the Compensation Committee of the Board. Dr. Wilke has years of experience in the biotechnology industry, with a focus on the pharmaceutical, diagnostic and therapeutic fields. Since August 2011, Dr. Wilke has served as President and Chief Executive Officer at CrossBridge International, LLC, an advisory firm she co-founded that specializes in integrating proprietary scientific developments with marketing and financial planning services.